idebenone has been researched along with Chronic Disease in 3 studies
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Oral treatment with idebenone 300 mg tid was started in seven patients 5 to 51 years after LHON onset." | 1.51 | Visual function in chronic Leber's hereditary optic neuropathy during idebenone treatment initiated 5 to 50 years after onset. ( Kircher, K; Pemp, B; Reitner, A, 2019) |
| "However, in experimental autoimmune encephalomyelitis, idebenone failed to affect disease incidence or onset when applied preventively, or to reduce disease severity when applied therapeutically." | 1.39 | The antioxidant idebenone fails to prevent or attenuate chronic experimental autoimmune encephalomyelitis in the mouse. ( Bros, H; Chanvillard, C; Dörr, J; Fiebiger, SM; Grobosch, T; Infante-Duarte, C; Janssen, A; Millward, JM; Paul, F, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pemp, B | 1 |
| Kircher, K | 1 |
| Reitner, A | 1 |
| Fiebiger, SM | 1 |
| Bros, H | 1 |
| Grobosch, T | 1 |
| Janssen, A | 1 |
| Chanvillard, C | 1 |
| Paul, F | 1 |
| Dörr, J | 1 |
| Millward, JM | 1 |
| Infante-Duarte, C | 1 |
| Koreshkina, MI | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-blinded, Placebo-controlled Trial of Idebenone in the Prevention of Episodic Migraine[NCT04151472] | Phase 3 | 180 participants (Anticipated) | Interventional | 2021-12-08 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 other studies available for idebenone and Chronic Disease
| Article | Year |
|---|---|
Visual function in chronic Leber's hereditary optic neuropathy during idebenone treatment initiated 5 to 50 years after onset.
Topics: Adult; Aged; Antioxidants; Chronic Disease; Follow-Up Studies; Forecasting; Humans; Male; Middle Age | 2019 |
The antioxidant idebenone fails to prevent or attenuate chronic experimental autoimmune encephalomyelitis in the mouse.
Topics: Animals; Antioxidants; Chronic Disease; Disease Models, Animal; Encephalomyelitis, Autoimmune, Exper | 2013 |
[The use of noben (idebenone) in the complex treatment of episodic and chronic migraine].
Topics: Adult; Antioxidants; Chronic Disease; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; | 2010 |